The COVID-19 pipeline: An unprecedented global clinical development effort

Posted by Kristyn Feldman on Mon, Apr 06, 2020

Parul Rewari, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

The global COVID-19 pandemic continues to dominate headlines, including near constant updates from the pharma industry and academic clinical researchers the world over. Last week, we looked at the clinical-stage programs aimed to address the novel coronavirus. This week, we have expanded our analysis to include a wider range of clinical programs, including phase IV studies, and additional sources of data regarding this quickly evolving landscape.


>
Read More

Clinical Development Risks and Issues in a COVID-19 World

Posted by Jonathan Rowe on Fri, Mar 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).


>
Read More

The Evolution of the Patient Experience

Posted by Ian Wilcox on Wed, Aug 28, 2019

With the healthcare business model constantly evolving, and new technologies continuously being adopted, the pharmaceutical landscape and the role of healthcare providers is sure to look radically different a few decades down the line.

I recently spoke with Dr. Roland Turck, managing partner of international biotech consulting firm TurckBio, about some of the biggest trends impacting pharma today, from AI to scientific advancements to bridging the divide between medical and commercial. Here are his thoughts on how the industry will evolve for patients and providers. 


>
Read More

How Pharma Companies Are Engaging Patients as R&D Partners

Posted by Kristyn Feldman on Wed, Nov 08, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This is the final post in a four-part series examining patient centricity within R&D.

To achieve true patient centricity in drug development, pharmaceutical companies need to follow four main principles: gain empathy for patients, uncover and meet patient needs, connect with patients and, finally, engage patients. By asking for and incorporating trial participant input at every level of R&D, the pharmaceutical industry can start to look at patients as true partners.


>
Read More

How Technology and Analytics Are Helping Big Pharma Improve Patient Engagement in R&D

Posted by Kristyn Feldman on Wed, Nov 01, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This is the third post in a four-part series examining patient centricity within R&D.

As drug development continues to grow more expensive and complex, and as patients expect to be more involved and empowered throughout the healthcare system, pharmaceutical companies are seeing the value in partnering with patients throughout the R&D process. The journey begins with building an understanding of and empathy for today’s patients, and then uncovering and meeting their needs. The third step is to hone in on how you connect with patients to increase the effectiveness of your communications.


>
Read More